50 years of research reveals that cannabis has been proven to help women overcome orgasm difficulty.

It’s Time to Recognize Female Orgasm Disorder and Other Women's Health Conditions as Qualifying Conditions for Medical Cannabis

Millions of women silently suffer with endometriosis, uterine fibroids, female orgasm disorder, ovarian cysts, and other chronic conditions that are systematically underdiagnosed and undertreated.

Empowering Women with Medical Cannabis

With years of research supporting cannabis as a treatment, we are advocating to add endometriosis, uterine fibroids, Female Orgasm Difficulty/Disorder, and ovarian cysts as qualifying conditions for medical cannabis so women can finally access the healing they need.

Our Impact

See how we’re making a difference through measurable results

All 4 Conditions

Approved in Illinois

FOD

Approved in Connecticut

FOD

Board-Level Approval in New Mexico

Testimonials

Trusted by Women Nationwide

The Women’s Cannabis Project is an initiative of the Female Orgasm Research Institute, a nonprofit advancing science, healing, and policy for women’s sexual health.

We also collaborate with the Female Orgasm Training Institute, our affiliated for-profit organization offering therapeutic education and professional training to support women in healing orgasm difficulty.

The Orgasm Hour Podcast

Get inspired by industry experts. Never miss an episode! Follow us on your favorite podcast platforms.

Frequently Asked Questions

Got Questions? We’ve Got Answers

The Women’s Cannabis Project was founded by Suzanne Mulvehill, PhD, a clinical sexologist, orgasmologist, and global advocate for advancing women’s health. Her work focuses on the therapeutic use of cannabis to access altered states of consciousness that can help rewire the brain, calm thoughts and emotional reactivity, and support healing from orgasm difficulty.

Dr. Mulvehill is the founder of the Female Orgasm Research Institute, the director of the Female Orgasm Training Institute, and host of The Orgasm Hour podcast—where science, healing, and pleasure come together in bold new conversations. She leads international efforts to shift public policy, expand access to treatment, and reimagine what’s possible in women’s health.

The Women’s Cannabis Project is a policy and public health initiative working to legitimize cannabis as a therapeutic option for multiple women’s conditions: endometriosis, uterine fibroids, female orgasm disorder, and ovarian cysts. We educate lawmakers, submit petitions to state governments, and advocate for the inclusion of FOD and other women’s health issues as qualifying conditions for medical cannabis.

FOD affects millions of women and is linked to significantly higher rates of mental health challenges, including 52.6% more PTSD, 29% more depression, 13% more anxiety, and 22% more prescription drug use compared to women without orgasm difficulty ( Mulvehill & Tishler,2024 ).

The Women’s Cannabis Project exists to change that—by advancing research, transforming access, and addressing one of the most neglected public health issues facing women today.

It also exists to address other women’s health issues that cause severe pain and suffering, and to support the community of women who have been left behind.

Women’s Cannabis Project officially launched in September 2023 to support the needs of women with female orgasm disorder.

In 2026, the Women’s Cannabis Project launched an update to include three more women’s conditions to its advocacy work: endometriosis, uterine fibroids, and ovarian cysts.

Female orgasmic disorder/difficulty (FOD) is one of the most common yet least treated health conditions affecting women today, linked to significantly higher rates of PTSD, depression, anxiety, and prescription drug use (Mulvehill & Tishler, 2024).

According to the national diagnostic standards, orgasm difficulty among premenopausal women has increased by 71% in recent years—yet no prescription drugs have been approved to treat it, and few therapeutic options exist.

In 2024, with the help of volunteers, the Women’s Cannabis Project submitted petitions in 11 U.S. states to recognize FOD as a qualifying condition for medical cannabis. While two states—Connecticut and Illinois—approved it, five states denied the petition, including Ohio, which rejected it twice.

This growing momentum—two states approving and five denying—reveals both the progress we have made and the deep disparities that remain. It shows exactly where our work is needed and why it must continue.

In 2024, Illinois was also petitioned by Chicago NORML, and the other three conditions became qualifying conditions, as well.

The Women’s Cannabis Project has launched a national policy initiative to recognize endometriosis, uterine fibroids, female orgasm disorder, and ovarian cysts as qualifying conditions for medical cannabis. With the help of dedicated volunteers, we submitted petitions in 11 U.S. states in 2024 for female orgasm disorder, including Oregon, Maryland, New Mexico, and Pennsylvania. To date, FOD has been approved in Connecticut, and all four conditions have been approved in Illinois—marking major wins for women’s health.

Despite these successes, five states have denied the petition for FOD so far, including Ohio, which rejected it twice. These rejections highlight the deep gaps in understanding and recognition of FOD— and other women’s health conditions— underscoring why this work remains urgent and essential.

Beyond policy advocacy, we educate the public through media coverage, online platforms, and podcasting, collaborate with researchers, and provide expert testimony to expand access, visibility, and legitimacy for women experiencing FOD.

There are many ways to support our work—by volunteering, partnering with us, or helping raise funds to advance research and advocacy. To connect, sign up for our research and advocacy newsletter here or email us at info@femaleorgasmresearch.org